Clinical Trials
52 trialsSATIATION
University Hospital, Brest
CardioTox
Hospital Sirio-Libanes
CardioProtEx
Technical University of Madrid
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Queen's University, Belfast
HER-SAFE
University College, London
Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
University College, London
PC-TOX
University College, London
SPIROTOX
University of Sao Paulo
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
National Cheng-Kung University Hospital
NEOCARDIO
Groupe Hospitalier Pitie-Salpetriere
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Ain Shams University
CONTROL
Humanitas Hospital, Italy
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients
Ain Shams University
The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.
Ruijin Hospital
EDIPE
Institut de cancérologie Strasbourg Europe
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Tanta University
The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients
D'Or Institute for Research and Education
Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
University Hospital, Essen
SPARE-HF
University Health Network, Toronto
SAFE
Azienda Ospedaliero-Universitaria Careggi
EIECC
Qianfoshan Hospital
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Affiliated Hospital of Qinghai University
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
GO fit Lab- Ingesport
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Ultromics Ltd
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
University of Glasgow
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Military Institute od Medicine National Research Institute
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
Peking University Third Hospital
AI
Taipei Medical University Shuang Ho Hospital
CANFLAX
St. Boniface Hospital
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Exercise Response After Revalidation in Cancer Patients
Universitair Ziekenhuis Brussel
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer
Samsung Medical Center
ERIC-ONC
University College, London
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
University of Athens
EARLY-CATCH
Radboud University Medical Center
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
Vilnius University
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
Stony Brook University
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
University of Sao Paulo General Hospital
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
M.D. Anderson Cancer Center
IPAC
University of Sao Paulo
COBC
Karolinska University Hospital
Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab
Unity Health Toronto
Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart
AHS Cancer Control Alberta
Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine
Fondazione del Piemonte per l'Oncologia
MANTICORE
AHS Cancer Control Alberta
PULSE-ECCho
McGill University Health Centre/Research Institute of the McGill University Health Centre
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes
Rambam Health Care Campus